Real-world first-line treatment patterns and outcomes in recurrent/advanced endometrial cancer patients in Europe

<b>Background:</b> The treatment patterns and clinical outcomes in recurrent/advanced endometrial cancer in Europe are not well known.<b>Materials & methods:</b> Endometrial Cancer Health Outcomes-Europe-First-Line is a multicenter, retrospective chart review study conducted in the UK, Germany, Italy, France and Spain. Patients diagnosed with recurrent/advanced endometrial cancer who initiated first-line systemic therapy between 1 July 2016 and 31 March 2020 were eligible.<b>Results:</b> Among 242 patients, median age was 69 years and 82.2% had stage IIIB-IV disease. In first-line, most patients received platinum-based chemotherapy (78.9%); others received endocrine therapy (6.2%), taxane monotherapy (5.8%) and nonplatinum or taxane-based chemotherapy (4.1%). Median real-world progression-free survival since first-line initiation was 10.8 months and median overall survival was 20.7 months.<b>Conclusion:</b> Poor prognosis with platinum-based first-line chemotherapy suggests significant unmet medical need.